Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : French Government
Deal Size : $0.2 million
Deal Type : Funding
Details : NFL-101 is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
November 01, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : French Government
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NFL Biosciences: Recruitment Completed for The PRECESTO Study
Details : NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is being evaluated for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is under phase I trials, for reduction in the desire to smoke, without any toxicity which also reduces tobacco aller...
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Bpifrance
Deal Size : $1.8 million
Deal Type : Funding
NFL Biosciences Receives € 1.7 Million In « Avance Innovation » Funding From Bpifrance
Details : The funding will be used to complete the CESTO II clinical study designed to evaluate the efficacy and safety of its NFL-101 (tobacco leaf protein) treatment as a smoking cessation therapy.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 20, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Bpifrance
Deal Size : $1.8 million
Deal Type : Funding
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : CEA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, NFL-Biosciences will use the CEA's molecular imaging resources to better understand the mechanism of action of NFL 101. NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 02, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : CEA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $2.7 million
Deal Type : Financing
NFL Biosciences Launches a Round of Fundraising for Approximately 2.5 Million Euros
Details : The funding will be used for the CESTO II phase II/III trial, aiming to demonstrate the efficacy of its botanical drug candidate NFL-101 for smoking cessation and and the PRECESTO trial, assessing the potential of NFL-101 for nicotine replacement therapi...
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
January 30, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $2.7 million
Deal Type : Financing
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NFL Biosciences: CESTO II Trial Progressing On Schedule
Details : NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is under phase I trials, for reduction in the desire to smoke, without any toxicity which also reduces tobacco aller...
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 20, 2023
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NFL BIOSCIENCES: Notice of Allowance of Its Patent In China
Details : NFL Biosciences has adopted a knowledge management and protection strategy that led it to submit two patent families granting it exclusive rights to its drug candidate NFL-101.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NFL Biosciences to Present at the H.C.wainwright 1st Annual Mental Health Conference
Details : NFL-101 (tobacco leaf protein), is a natural product based on a standardized extract of tobacco leaf patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 24, 2022
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Artemis Biotech
Deal Size : Undisclosed
Deal Type : Partnership
NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India
Details : Under the partnership to develop NFL-101, the company’s drug candidate Tobacco leaf protein for smoking cessation, for the Indian market with Themis Medicare Ltd., will purchase Active Pharmaceutical Ingredient (API) from NFL Biosciences.
Product Name : NFL-101
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Tobacco Leaf Extract
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Artemis Biotech
Deal Size : Undisclosed
Deal Type : Partnership